Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Amgen Q3 2026 Results: Net Income $3.86B, Up 20.1% YoY

Amgen reported total revenues of $10.37 billion for the third quarter of 2026, an 8% increase compared to the same period in 2025, driven primarily by product sales growth. Net income rose to $3.86 billion, or $7.08 per diluted share, benefiting from higher operating income and significant other income gains.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue10,365.09,557.0
Profit before tax4,686.03,921.0
Net income3,864.03,216.0
EPS (diluted, $ a share)$7.08$5.93

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+20.1%
Revenue, year on year+8.5%
Operating margin35.8%
Source

10-Q filed with the SEC, NASDAQ: AMGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Amgen Inc: key numbers

Share price
$462.32Close, Nov 16
Market cap
$250B
Shares outstanding
540.91MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Amgen Inc

All →
4:06 PM ET 8-K
Financial Results

Amgen Financial Results

Amgen reported third quarter 2026 financial results with total revenues increasing 8% year-over-year to $10.4 billion, driven by volume growth across its commercial portfolio. GAAP EPS rose 19% to $7.08, while the company generated $3.7 billion in free cash flow during the period.

Term
Q3 2026

“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”

Robert A. Bradway, chairman and chief executive officer
6:01 AM ET 8-K
Leadership Change

Amgen Leadership Change

Amgen Inc. has appointed David W. Gibbs, the former CEO of Yum! Brands, to its Board of Directors, effective immediately. Mr. Gibbs will serve on the Audit and Compensation committees, bringing the total board size to 13 directors. He will receive the company's standard non-employee director compensation, including a pro-rated annual cash retainer and restricted stock units.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.